News

Published on 21 Jul 2021 on Zacks via Yahoo Finance

ALXN vs. TECH: Which Stock Is the Better Value Option?


Article preview image

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alexion Pharmaceuticals (ALXN) and Techne (TECH). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.

Right now, both Alexion Pharmaceuticals and Techne are sporting a Zacks Rank of # 2 (Buy). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one factor that value investors are interested in.

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

Bayer Aktiengesellschaft’s BAYRY wholly owned subsidiary, BlueRock Therapeutics LP, announced tha...

MSN News 24 Jul 2021

Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?

The market expects Alexion Pharmaceuticals (ALXN) to deliver a year-over-year increase in earning...

Zacks via Yahoo Finance 22 Jul 2021

ALXN vs. TECH: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably al...

Zacks via Yahoo Finance 21 Jul 2021

Moderna Enters the S&P Amid Delta Variant Fears – Should You Invest?

Moderna entered the S&P 500 today, amid increasing global fears around the Delta variant. The sto...

GoBankingRates via AOL 21 Jul 2021

Moderna stock 'has taken on a life of its own,' jumps 4% in S&P debut

Moderna (MRNA) began trading on the S&P 500 on Wednesday, replacing Alexion Pharmaceuticals Inc. ...

Yahoo Finance 21 Jul 2021

Moderna being added to S&P 500

The biotech company, which has already delivered over 100 million COVID-19 vaccines, will replace...

Fox Business 21 Jul 2021

Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day

Shares of Alexion Pharmaceuticals Inc. advanced 1.70% to $182.50 Tuesday, on what proved to be an...

Market Watch 20 Jul 2021

Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study

Alexion Pharmaceuticals, Inc. ALXN announced that the late-stage study evaluating its long-acting...

MSN News 18 Jul 2021

Moderna to join S&P 500, shares jump after hours

Moderna Inc (MRNA.O) will join the S&P 500 index (.SPX) as of the start of trading on July 21, re...

Reuters 15 Jul 2021

Moderna Climbs as S&P 500 Set to Welcome Covid Vaccine Maker

The company, whose messenger-RNA vaccine has helped to fight the Covid-19 pandemic, will replace ...

Bloomberg 15 Jul 2021